Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Aidan P. Toner
Observed names:
A P Toner,
Aidan Toner,
Toner, Aidan
Institution:
Ollscoil na Gaillimhe – University of Galway
Observed institutions:
Duke University,
National University of Ireland,
Ollscoil na Gaillimhe – University of Galway,
Duke Medical Center
ORCID:
0000-0003-4000-2871
Observed ORCID:
0000-0003-4000-2871
OpenAlex ID:
A5071876938
Benefits, challenges, critical success factors and motivations of Quality 4.0 – A qualitative global study
2022
·
Jiju Antony
, Olivia McDermott
, et al.
·
Total Quality Management & Business Excellence
·
134
Induction of Krüppel-Like Factor 5 Expression by Androgens Results in Increased CXCR4-Dependent Migration of Prostate Cancer Cellsin Vitro
2009
·
Daniel E. Frigo
, Andrea B. Sherk
, et al.
·
Molecular Endocrinology
·
80
PDF
The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance
2013
·
A P Toner
, F McLaughlin
, et al.
·
British Journal of Cancer
·
13
PDF
Lean, Green and Sustainability: 8th IFIP WG 5.7 European Lean Educator Conference, ELEC 2022, Galway, Ireland, November 22–24, 2022, Proceedings
2023
·
Olivia McDermott
, Angelo Rosa
, et al.
·
IFIP advances in information and communication technology
·
4
Electronic validation systems as an aid to quality and regulatory compliance in the medical device and pharmaceutical industries
2025
·
Olivia McDermott
, Neasa Conroy
, et al.
·
The TQM Journal
·
2
Preclinical assessment of the novel compound EL102 in prostate cancer
2015
·
Toner, Aidan
·
Arrow@dit (Dublin Institute of Technology)
Further preclinical assessment of compound EL102 in the treatment of prostate cancer.
2014
·
Aidan P. Toner
, Francis J. Giles
, et al.
·
Journal of Clinical Oncology
Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro.
2012
·
Sharon A. Glynn
, Aidan Toner
, et al.
·
Journal of Clinical Oncology
Abstract B18: EL102: A novel dual inhibitor which demonstrates additive prostate cancer inhibitory activity in combination with docetaxel in vitro and in mouse models
2012
·
Aidan Toner
, Fiona McLaughlin
, et al.
·
Cancer Research
Show more works
View as search
Works count:
9
Citation count:
233
H-index:
4
I10-index:
3
Year
Topic
Type